Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials
|
|
- Alberta Violet Perkins
- 5 years ago
- Views:
Transcription
1 The European Journal of Heart Failure 4 (2002) Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials Jeffrey W.H. Fung, Skiva K.W. Chan, Leata Y.C. Yeung, John E. Sanderson* Division of Cardiology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital Shatin, NT, Hong Kong SAR, PR China Received 29 May 2001; received in revised form 26 November 2001; accepted 12 January 2002 Abstract Background: Beta-adrenergic blockade is of proven value in chronic heart failure. It is uncertain, however, if beta-blockade provides a similar degree of clinical benefit for heart failure patients with atrial fibrillation (AF) as those in sinus rhythm (SR). Aims: To compare the effectiveness of beta blockade in patients with heart failure and AF. Methods: Patients with chronic heart failure were randomized to treatment (double blind) with metoprolol 50 mg twice daily or carvedilol 25 mg twice daily in addition to standard therapy. Response was assessed after 12 weeks by a quality of life questionnaire, New York Heart Association class, exercise capacity (6-min walk test), radionucleotide ventriculography for LVEF, 2-D echocardiography measurement of left ventricular (LV) dimensions and diastolic filling and 24-h electrocardiograph monitoring to assess heart rate changes. Results: Both beta-blockers produced significant improvements in LVEF in both the SR group: (q6"10% at 12-week, P-0.001) and the AF group: (q11"9% at 12-week, P-0.05). However, significant improvement in symptoms (P-0.001) and exercise capacity (P-0.001) were observed only in the SR group but not in the AF group despite a significant improvement in LVEF. Conclusion: Beta-blockers were effective in improving LV ejection fraction in chronic heart failure patients in either SR or AF but had less effect on symptoms and exercise capacity in those with AF European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved. Keywords: Atrial fibrillation; Beta-blockers; Heart failure 1. Introduction It is well proven that beta-adrenergicblockade is useful for patients with chronic heart failure w1,2x. The MERIT-HF study and several other studies have provided strong evidence supporting favourable effects of b- blockade on left ventricular (LV) ejection fraction and the combined risk of death and hospitalization for heart failure w3,4x. Metoprolol and carvedilol were the betablockers studied in these trials w1 4x. The effects of metoprolol and carvedilol in the treatment of chronic heart failure are comparable, as we have previously reported w5x. It is estimated that atrial fibrillation (AF) was present in 15 30% of patients with dilated cardiomyopathy and moderate to advanced heart failure w6 8x. Beta-blockers have been shown to reduce arrhythmic *Corresponding author. Tel: q ; fax: q address: jesanderson@cuhk.edu.hk (J.E. Sanderson). events and have a significant impact on AF w9 11x. However, there is limited data about the clinical benefit, if any, of using beta-blockers in heart failure patients with AF. Therefore, we have analyzed two previous prospective trials w5,12x to compare the clinical benefits of beta-blockers, either metoprolol or carvedilol, in the treatment of chronic heart failure patients with either sinus rhythm (SR) or AF. Response was assessed by symptoms, exercise capacity, LV systolic and diastolic function and heart rate changes over a 3-month period. 2. Methods 2.1. Trial design Both trials were prospective, parallel group, double blind-controlled trials with similar design w5,12x. Inclusion criteria of the two studies were identical. Patients with typical symptoms of heart failure and reduced LV /02/$ - see front matter 2002 European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved. PII: S Ž
2 490 J.W. Fung et al. / The European Journal of Heart Failure 4 (2002) ejection fraction (-0.45) were recruited into the studies. The first study compared metoprolol to celiprolol in patients with chronic heart failure w12x and the second study compared metoprolol to carvedilol w5x. Patients were divided into SR and AF groups. Only patients who received either metoprolol or carvedilol were recruited for analysis because the beneficial effects of these two beta-blockers have been well proven in other heart failure trials w1 4x. There was a 4-week titration period, increasing the dose of carvedilol from to 25 mg twice daily and metoprolol from 6.25 to 50 mg twice daily. Doses were increased at weekly intervals. Maintenance of doses was continued for 8 weeks (total of 12 weeks of treatment). At the end of 12 weeks, baseline measurements were repeated. Clinical assessment was carried out at 1, 2, 4 and 8 weeks. Compliance was checked by counting the remaining capsules at each visit Study objectives To compare the clinical benefits of beta-blockers in heart failure patients with either SR or AF, by assessment of symptoms (using the Minnesota Quality of Life Heart Failure Questionnaire), exercise capacity (6-min walk test), LV ejection fraction (measured by radionucleotide ventriculography and echocardiography) and heart rate changes (24-h ambulatory electrocardiograph (ECG) monitoring). The primary end points were symptom score, exercise time and LV ejection fraction. The study had a 90% power to detect a 55% reduction in symptoms score, a 20% increase in the 6-min walk time and a 12% increase in LV ejection fraction from baseline for each group, all of which would be considered clinically significant Study patients Patients with a clinical diagnosis of chronic heart failure who were on standard therapy with diuretics, digoxin- and angiotensin-converting enzyme inhibitors and with a LV ejection fraction of (by radionucleotide ventriculography) were recruited. Patients were excluded if they had significant valvular heart disease as the etiology of LV dysfunction, active myocarditis, unstable angina, a documented history of sustained ventricular tachycardia or symptomatic nonsustained ventricular tachycardia or second- or third-degree atrioventricular block. Patients with chronic obstructive lung diseases, asthma, long-term alcohol or drug abuse or chronic renal failure (serum creatine )200 mmolyl), hepatic, hematological, neurological or collagen vascular disease were excluded. All subjects gave written informed consent, and the study was approved by the Ethics Committee of the Faculty of Medicine, the Chinese University of Hong Kong Study measurements Baseline measurements included assessment of symptoms using the Minnesota Heart Failure Symptom Questionnaire, New York Heart Association (NYHA) class and routine clinical examination (pulse, heart rate, sitting and standing blood pressure, examination of jugular venous pressure, position of the apex beat and presence or absence of a heart murmur or lung rales). A 6-min corridor walk test was carried out. Two baseline walk tests were carried out and the results averaged. Routine 2-D Doppler echocardiography was performed with measurement of LV dimensions. Pulse-wave Doppler echocardiography was performed to assess mitral inflow velocities. The usual variables were measured: peak early mitral filling velocity (E wave), peak atrial filling velocity (A wave), ratio of the peak early and atrial filling velocities (EyA), deceleration time of the E wave (DT) and isovolumicrelaxation time, as previously described w13x. Radionucleotide ventriculography was used to assess LV ejection fraction in the usual way. A 24-h ambulatory ECG monitoring was undertaken using the Marquette (Milwaukee, Wisconsin) MARS 8000 analyzer. Maximum, average and minimum heart rate analyses were undertaken. Routine blood laboratory tests were performed at baseline, and at 4 and 8 weeks Statistical analysis Differences between the AF and SR groups were carried out by repeated-measures analysis of variance for continuous variables (ANOVA) with Barlets test with homogeneity test if P-0.05, Friedman s test for non-parametric data and Fisher exact test for differences between proportions. Differences between baseline and week 12 within groups were tested by paired t-tests, and Wilcoxon matched pairs signed ranks test for nonparametricdata. The results are expressed as mean"s.e.m. Differences were considered significant if P Results 3.1. Subjects Sixty-three patients with a mean LV ejection fraction of 26"10% were in SR while 12 patients with a mean LV ejection fraction of 26"7% were in AF. In the SR group, 42 patients were taking metoprolol and the rest were taking carvedilol. In the AF group, 5 were taking metoprolol and 7 were taking carvedilol. There were no significant differences in age, gender or other baseline characteristics except that the AF group had lower exercise capacity than the SR group (Table 1). The majority of patients had idiopathicdilated cardiomyopathy (44%) with ischemic cardiomyopathy as the etiology in 25% and hypertensive heart disease in 30%.
3 J.W. Fung et al. / The European Journal of Heart Failure 4 (2002) Table 1 Baseline clinical characteristics of study patients Sinus rhythm Atrial fibrillation P-value (ns63) (ns12) Age (years) 58.1 (1.6) 64.3 (3.4) 0.13 Range Gender Male 50 9 Female 13 3 Etiology IDC 29 4 ICM 17 2 HTHD 17 6 NYHA functional class II 25 3 NYHA functional class III 37 9 NYHA functional class IV 1 0 Symptom questionnaire score 16.1 (1.5) 15.4 (4.9) 0.86 ETT (6-min walk, feet) 1210 (27) 908 (72) Baseline blood pressure (mmhg) 125 (3)y76 (2) 127 (7)y73 (3) 0.70y0.58 Heart rate (beatsymin) 84.5 (1.7) 78.2 (2.7) 0.12 LVEF (%) 26.1 (1.3) 26.1 (2.3) 1.0 LVEDD (cm) 7.0 (0.1) 6.2 (0.3) 0.01 FS (%) 14.2 (0.6) 13.8 (1.1) 0.77 Treatment Frusemide 57 (90%) 11 (92%) Frusemide mean dose (mg) 59.3 (5.3) 69.1 (14.1) 0.47 ACEIyAIIRA 58 (92%) 11 (92%) Nitrates 40 (63%) 7 (58%) Values are mean"s.e.m.; ACEI, angiotensin-converting enzyme inhibitor; AIIRA, angiotensin II receptor antagonist; ETT, exercise tolerance test; FS, LV fraction shortening; HD, heart disease; HTHD, hypertensive heart disease; ICM, ischemic cardiomyopathy; IDC, idiopathic dilated cardiomyopathy; LVEDD, LV end-diastolic dimension; LVEF, LV ejection fraction (gated blood pool scan). All but one patient were taking an angiotensin-converting enzyme inhibitor or an angiotensin II receptor antagonist. The average daily dose of frusemide was similar in both groups Withdrawals In the SR group, 7 patients did not complete the study. The reason for withdrawal was mainly worsening of symptoms, in particular, weakness, dizziness and dyspnoea. One patient developed angioneuroticedema. In the AF group, 3 patients did not complete the study and the reasons for withdrawal were similar to that of the SR group. There was no difference between the SR and AF groups Symptoms The results of the symptom (quality of life) questionnaire score and assessment of NYHA functional class are shown in Table 2. A highly significant reduction in symptom questionnaire score was observed in SR group (P-0.001) but not in AF group. Neither the SR nor AF groups had any reduction of NYHA class though a trend (Ps0.07) of reduction was observed in the SR group after 12-weeks of beta-blocker therapy. However, there were no significant differences between SR and AF in terms of NYHA class (Ps0.104) and quality of life questionnaire score (Ps0.61) at the end of the study Blood pressure and heart rate (Table 2) At 12 weeks, beta-blockers produced a highly significantly reduction in systolic and diastolic blood pressures compared with baseline in SR group. In AF group, a reduction in systolic and diastolic blood pressures was also observed. At the end of the study, blood pressures were significantly lower in the AF group when compared to the SR group (Ps0.012). A significant reduction of maximum, average and minimum heart rate was observed in both the SR and AF groups at 12 weeks when compared to baseline. There was no difference in average heart rate in both groups at 12 weeks (64.6"1.4 beatsymin in SR and 63.4"2.6 beatsymin in AF) Exercise capacity (Table 2) With similar degree of LV ejection fraction, the AF group had worse exercise capacity than the SR group at baseline (Table 1). At 12 weeks, a significant improve-
4 492 J.W. Fung et al. / The European Journal of Heart Failure 4 (2002) Table 2 Effects of beta-blockers on symptoms, exercise capacity, blood pressure and heart rate (Mean"SEM) SR group AF group SR vs AF at 12- Baseline 12 weeks Baseline 12 weeks week, P-value Symptom questionnaire score 16.1 (1.5) 6.8 (1.1) *** 15.4 (5.0) 8.4 (3.6) 0.61 NYHA functional class I II III IV Mean 2.6 (0.07) 2.04 (0.07) 2.75 (0.13) 2.33 (0.17) Blood Pressure (mmhg) SBP 125 (3) 117 (3) ** 127 (7) 98 (8) * DBP 76 (2) 70 (2) *** 74 (3) 63 (4) * 0.09 Heart Rate (HR) (beatsymin) Maximum HR (2.3) (2.1) *** (13.0) (10.1) * Average HR 84.5 (1.7) 64.6 (1.4) *** 78.2 (2.7) 63.4 (2.6) ** 0.76 Minimum HR 59.7 (1.7) 48.6 (1.1) *** 50.0 (3.0) 41.7 (3.2) ** ETT (6-min walk, feet) 1210 (27) 1323 (31) *** 908 (71) 984 (90) DBP, diastolic blood pressure; ETT, exercise tolerance time; NYHA, New York Heart Association; SBP, systolic blood pressure. *** P ** P * P-0.05 week 12 vs. baseline. ment in exercise capacity as measured by 6-min walk test was observed in the SR group only. Moreover, exercise capacity at 12 weeks in the SR group was better than that in the AF group (1323"31 feet vs. 984"90 feet, respectively, P-0.001) LV systolic and diastolic functions (Table 3) Both groups showed significant improvement in LV ejection fraction with beta-blocker therapy. There was no difference in LV ejection fraction between the two groups at 12 weeks (32"1.6% in SR and 37"5.1 in AF). At 12 weeks, the SR group, but not the AF group, showed a significant reduction in LV end-diastolic dimension. Beta-blockers produced no change in peak mitral E wave velocity but prolonged the deceleration time of the mitral E value towards normal in both groups. 4. Discussion In this 3-month study comparing the clinical efficacy of beta-blocker therapy in chronic heart failure patients with either SR or AF, we have demonstrated that betaadrenergic blockade significantly improves LV ejection fraction in both groups. However, the benefit of betablocker therapy in improving exercise capacity and quality of life as reflected by the symptom questionnaire score could only be demonstrated in the SR group. Betablocker therapy lowered blood pressures in both groups. Table 3 Effects of beta-blockers on systolic and diastolic LV function SR group AF group SR vs AF at 12- Baseline Week 12 Baseline Week 12 week, P-value LVEF % 26"1.2 32"1.6 *** 26"2.3 37"5.1 * 0.32 LV FS 14.2" "0.8 *** 13.8" "2.5 * 0.07 LV edd (cm) 7.0" "0.2 ** 6.2" " Mitral E (cmys) 11.3" " " " Mitral A (cmys) 9.1" "3.3 NA NA NA EyA ratio 1.5" "0.1 NA NA NA Mitral DT (ms) 145"9 208"11 *** 147"19 223"26 *** 0.6 LV edd, LV end-diastolic dimension; LVEF, LV ejection fraction; LVFS, LV fractional shortening; mitral A, peak velocity of mitral atrial wave; mitral DT, deceleration time of mitral E wave; mitral E, peak velocity of mitral early filling wave; NA, not applicable. *** P ** P * P-0.05 week 12 vs. baseline.
5 J.W. Fung et al. / The European Journal of Heart Failure 4 (2002) Both groups showed a marked reduction in heart rates with beta-blocker therapy. With regard to LV diastolic function, significant prolongation of mitral E deceleration time was observed in both groups. In our study, 16% of patients with chronic heart failure were in AF. Such a proportion is consistent with other studies which range from 15 to 30% w6 8x. The proportion of heart failure patients with AF in V-HeFT I w14x was 16% and in V-HeFT II w15x was 13%. Thus, our study cohort is quite similar to other heart failure studies. However, the small number of patients in AF when compared with those in SR makes statistical analysis difficult w6x. In this study, beta-blocker therapy was shown to be equally effective in improving LV systolic function in heart failure patients with either AF or SR. In a retrospective analysis of the US Carvedilol Heart Failure Trials Program w16x, a similar degree of improvement in LV ejection fraction in patients with AF by carvedilol when compared to placebo was also observed. There was a non-significant trend of reduction in combined endpoints of death or heart failure hospitalization in the carvedilol group. However, different results were observed in the CIBIS II trial w17x using bisoprolol. The survival benefit and reduction in heart failure hospitalization by bisoprolol was not observed in those patients in AF. This suggests that different beta-blockers may not have the same benefits to heart failure patients with AF. It is interesting to note that, although the LV ejection fraction was similar in both groups at baseline and end of week 12 in the present study, patients in AF had a worse exercise capacity and were more symptomatic than patients in SR. Moreover, significant improvement in exercise capacity and symptoms by beta-blockers was only observed in the SR group. It has also been shown that baseline heart rate and heart rate changes are significantly related to prognosis in patients with heart failure w17x. In the present study, however, rate control differences after beta-blocker therapy cannot explain the difference as the maximum, average and minimum heart rates were similar in both groups after 12 weeks of therapy. There are two possible explanations why patients in AF were more symptomaticand had worse exercise capacity. First, statistical error might be responsible, as the sample size of patients in AF was small. The second explanation is that it might be related to the physiological impact of ventricular rate irregularity. In a meta-analysis, Wood et al. reported that ablation and pacing therapy in chronic refractory AF can significantly improve quality of life w18x. Controlled regular ventricular rate provided by pacing might contribute to this improvement. Clark et al. w19x reported an acute pacing study in patients after atrioventricular nodal (AVN) ablation. Pacing with a regular rate in the VVI mode at the average rate of AF resulted in higher cardiac output than pacing at the same rate and rhythm in the VVT mode triggered to the RR intervals present in AF. Daoud et al. w20x reported that cardiac output was higher with regular vs irregular right ventricular apical pacing at two paced sites in patients after AVN ablation. Irregular ventricular rate in AF may influence preload, afterload, or inotropic state in turn affecting ventricular performance. The marked beat-to-beat variability in the intensity of pulse and blood pressures is due to changes in LV contractility, according to Frank Starling mechanism w21x. Postextrasystolic potentiation occurs following a short long RR sequence w22x. In heart failure patients, this beat-to-beat variability in LV contractility may have deleterious effects by further exacerbating increases in sympathetictone and salt and water retention present as compensatory responses. These physiological changes may explain why heart failure patients in AF have more symptoms and worse exercise capacity. However, there are conflicting results in terms of any difference in exercise tolerance between the AF and SR groups. In the V-HeFT I w14x study using vasodilator therapy, peak oxygen capacity was similar in both the AF and SR groups. In the V-HeFT II study w15x, there was no difference in change in peak oxygen consumption during the first 2 years but patients with AF showed a decline at 2.5 years. Data on beta-blocker therapy in patients with AF or SR in terms of exercise capacity is limited. Our study may contribute to this information. In patients with dilated cardiomyopathy, restrictive filling pattern with short mitral E deceleration time was associated with worse prognosis w23 25x. Prolongation of mitral E deceleration time in both groups by betablocker reflected an improvement in diastolic function and possibly might have an impact on survival improvement. There is controversy about the choice and doses of beta-blocker in patients with heart failure. Gilbert et al. w26x reported that carvedilol may be associated with greater improvement in NYHA functional class. In our previous double blind-randomized study w5x, both metoprolol and carvedilol were equally effective in improving LV ejection fraction, quality of life and exercise capacity. The observed difference between SR and AF groups in this study is probably independent of the choice of betablocker. The dose (50 mgyd) of carvedilol in the current study was comparable to the mean dose (44 49 mgyd) of this drug used in the multicentre trials w1,2,27x showing a reduction in morbidity and mortality in patients with heart failure. The dose (100 mgyd) of metoprolol in this study was slightly lower than that in Metoprolol in Dilated Cardiomyopathy Trial (108 mgy d) w28x. In the MERIT-HF study w3,4x, slow-release form of metoprolol succinate was used and the adjusted equivalent dose of metoprolol tartrate was 119 mgyd.
6 494 J.W. Fung et al. / The European Journal of Heart Failure 4 (2002) Study limitations This study had a relatively small number of patients, especially in the AF group, and there is a possibility of a type II error. It was not powered to detect any differences in mortality and was designed to determine if there were any obvious or major differences in clinical efficacy, especially in terms of symptoms, quality of life and exercise capacity between the SR and AF groups. To this end, we used a wide range of well-validated techniques including the Minnesota Heart Failure Symptom Questionnaire and the 6-min walk test. Several studies have now demonstrated a clear independent inverse relation between the 6-min walk test and both mortality and morbidity w29x. 5. Conclusion In this study, we have confirmed the beneficial effects of the beta-blockers metoprolol and carvedilol, in improving LV ejection fraction in chronic heart failure patients, in either SR or AF. However, the improvement in exercise capacity and quality of life by beta-blocker therapy, could only be observed in patients in SR. References w1x Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001;344: w2x Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 1996;334: w3x MERIT-HF Study Group, Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CRyXL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000;283: w4x MERIT-HF Study Group. Effects of metoprolol CRyXL in chronic heart failure: metoprolol CRyXL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353: w5x Sanderson JE, Chan SKW, Yip G, et al. Beta-Blockade in heart failure. A comparison of carvedilol with metoprolol. J. Am. Coll. Cardiol. 1999;34: w6x Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. Circulation 1993;87(Suppl. VI):VI-102 VI-110. w7x Doval HC, Nul DR, Grancelli HO, et al. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;334: w8x Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N. Engl. J. Med. 1995;333: w9x Lechat P, Packer M, Chalon S, et al. Clinical effects of b- adrenergic blockade in chronic heart failure. A meta-analysis of double-blind placebo-controlled, randomized trials. Circulation 1998;98: w10x Cleland JGF, Bristow EE, Remmes WY, et al. Beta blocking agents in heart failure. Should they be used? Eur. Heart J. 1996;17: w11x Narayan SM, Cain ME, Smith JM. Atrial fibrillation. Lancet 1997;350: w12x Sanderson JE, Chan SKW, Yu CM, et al. b-blockers in heart failure: a comparison of a vasodilating b-blocker with metoprolol. Heart 1998;79: w13x Cohen GJ, Pietrolungo JF, Thomas JD, et al. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J. Am. Coll. Cardiol. 1996;27: w14x Cohn JN, Archibald DG, Ziesche S, et al. Effect of therapy on mortality in chronic congestive heart failure: a result of Veterans Administration Cooperative Study (V-HeFT). N. Engl. J. Med. 1986;314: w15x Cohn JN, Johnson G, Ziesches S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 1991;325: w16x Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am. Heart J. 2001;142: w17x Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103: w18x Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 2000;101: w19x Clark DM, Plumb VJ, Kay GN. The hemodynamics of atrial fibrillation: the independent effect of an irregular RR interval. Circulation 1995;95:I 141 (Abstract). w20x Daoud E, Weiss R, Bahu M, et al. Effect of a regular and irregular ventricular rhythm on cardiac output. PACE 1996;19:691 (Abstract). w21x Noble MIM. The Frank-Starling curve. Clin. Sci. Mol. Med. 1978;54:1 7. w22x Hard SMC, Noble MIM, Seed WA. Postextrasystolicpotentiation and its contribution to the beat-to-beat variation of the pulse during atrial fibrillation. Circulation 1992;86: w23x Rihal CS, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation 1994;90: w24x Little WC, Ohno M, Kitzman DW, Thomas JD, Cheng CP. Determination of left ventricular chamber stiffness from the time of deceleration of early ventricular filling. Circulation 1995;92: w25x Sanderson JE, Yeung LY, Chan S, et al. Effect of b-blockade on baroreceptor and autonomic function in heart failure. Clin. Sci. 1999;96: w26x Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and anti-adrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94: w27x Australia New Zealand Heart Failure Research Collaborative Group. Randomized placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349: w28x Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group, Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342: w29x Yusuf S, Tsuyuki R. Using exercise endpoints in heart failure trials: design considerations. Eur. Heart J. 1996;17:4 6.
Beta-Blockade in Heart Failure A Comparison of Carvedilol With Metoprolol
Journal of the American College of Cardiology Vol. 34, No. 5, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00367-8 A Comparison
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationHeart failure. Complex clinical syndrome. Estimated prevalence of ~2.4% (NHANES)
Heart failure Complex clinical syndrome caused by any structural or functional impairment of ventricular filling or ejection of blood Estimated prevalence of ~2.4% (NHANES) Etiology Generally divided into
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationDiastolic Dysfunction in the Presence of Left Ventricular Systolic Dysfunction: Implications of ß-Adrenergic Blocking Therapy
DIASTOLIC DYSFUNCTION CHF MARCH/APRIL 2001 71 Diastolic Dysfunction in the Presence of Left Ventricular Systolic Dysfunction: Implications of ß-Adrenergic Blocking Therapy The contribution of left ventricular
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationThe Effects of Ranitidine in Chronic Heart Failure Patients
Keerati Hantrakool, MD, and Jarkarpun Chaipromprasit, MD. Division of Cardiology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Abstract Objectives: To determine
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationDobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure
Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure Yuksel Cavusoglu, KU Mert, A Nadir, F Mutlu, E Gencer, T Ulus, A Birdane
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More informationLong-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure
Long-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure Naomi Naoki Yoko Yoshie Hiroshi KAWASHIRO, MD MATSUDA, MD ENDO, MD UCHIDA, MD KASANUKI, MD, FJCC
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationCase 1: A 54-year-old man with
CLINICIAN UPDATE -Blockers in Chronic Heart Failure Mihai Gheorghiade, MD; Wilson S. Colucci, MD; Karl Swedberg, MD Case 1: A 54-year-old man with a history of myocardial infarction (MI) presented with
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationCongestive Heart Failure or Heart Failure
Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?
More informationThe effect of altering heart rate on ventricular function in patients with heart failure treated with h-blockers
The effect of altering heart rate on ventricular function in patients with heart failure treated with h-blockers Simon D.R. Thackray, MRCP, a Justin M. Ghosh, MRCP, Graham A. Wright, PhD, b Klaus K.A.
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationMetoprolol CR/XL in Female Patients With Heart Failure
Metoprolol CR/XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) Jalal K. Ghali, MD; Ileana L.
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationTriastuti et al., IJPSR, 2012; Vol. 3(9): ISSN:
IJPSR (2012), Vol. 3, Issue 09 (Research Article) Received on 11 May, 2012; received in revised form 14 June, 2012; accepted 21 August, 2012 ROLE OF BISOPROLOL ADDING TO ANGIOTENSIN CONVERTING ENZYME (ACE)
More informationAtrial fibrillation (AF) is the most common sustained
Effect of Atrial Fibrillation and an Irregular Ventricular Response on Sympathetic Nerve Activity in Human Subjects Stephen L. Wasmund, PhD; Jian-Ming Li, MD, PhD; Richard L. Page, MD; Jose A. Joglar,
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationHeart Failure and Cardiomyopathy Center, Division of Cardiology, North Shore University Hospital, Manhasset, NY
NEUROHORMONAL ANTAGONISTS IN THE POST-MI PATIENT New Evidence from the CAPRICORN Trial: The Role of Carvedilol in High-Risk, Post Myocardial Infarction Patients Jonathan D. Sackner-Bernstein, MD, FACC
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationBeta-Blockers and Outcome in Heart Failure and Atrial Fibrillation A Meta-Analysis
JACC: Heart Failure Vol. 1, No. 1, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN 2213-1779/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jchf.2012.09.002 CLINICAL RESEARCH
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationE/Ea is NOT an essential estimator of LV filling pressures
Euroecho Kopenhagen Echo in Resynchronization in 2010 E/Ea is NOT an essential estimator of LV filling pressures Wilfried Mullens, MD, PhD December 10, 2010 Ziekenhuis Oost Limburg Genk University Hasselt
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationTreatment of Heart Failure: Current Recommendation Waiz A
Treatment of Heart Failure: Current Recommendation Waiz A The impaired left ventricular emptying that characterizes heart failure may result from a variety of cardiac diseases, including myocardial ischaemia
More informationMethods. progression of left ventricular systolic dysfunction in. (J Am Coll Cardiol 1998;32: ) 1998 by the American College of Cardiology
695 Atrial Fibrillation Is Associated With an Increased Risk for Mortality and Heart Failure Progression in Patients With Asymptomatic and Symptomatic Left Ventricular Systolic Dysfunction: A Retrospective
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationEpidemiology of Symptomatic Heart Failure in the U.S.
William T. Abraham, MD, FACP, FACC, FAHA, FESC Professor of Medicine, Physiology, and Cell Biology Director, Division of Cardiovascular Medicine Deputy Director Davis Heart and Lung Research Institute
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationEffect of Heart Rate on Tissue Doppler Measures of E/E
Cardiology Department of Bangkok Metropolitan Administration Medical College and Vajira Hospital, Bangkok, Thailand Abstract Background: Our aim was to study the independent effect of heart rate (HR) on
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationJournal of the American College of Cardiology Vol. 33, No. 4, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(98)00675-5 Beta-Adrenergic
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationHeart Failure Overview. Dr Chris K Y Wong
Heart Failure Overview Dr Chris K Y Wong Heart Failure: A Growing, Global Health Issue Heart Failure 23 Million Afflicted Global Impact Worldwide ~23 million peopleworldwide afflicted with CHF 1 Exceeds
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationThe NEW Heart Failure Guidelines
The NEW Heart Failure Guidelines Daily Practice HF scenario of the Case Presentations HF as a complex and heterogeneous syndrome Several proposed pathophysiological mechanisms involving the heart and the
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationعلم االنسان ما لم يعلم
In the name of Allah, the Beneficiate, the Merciful ق ال هللا تعالي: 5 الدى علم بالق لم 4 علم االنسان ما لم يعلم سورة العلق It is He (Allah), Who has taught by the pen He has taught man which he did not
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationThoranis Chantrarat MD
Device Therapy in Heart Failure Thoranis Chantrarat MD 1 Scope of presentation Natural history of heart failure Primary and secondary prevention ICD and its indication CRT and its indication 2 Severity
More informationPeripartum Cardiomyopathy. Lavanya Rai Manipal
Peripartum Cardiomyopathy Lavanya Rai Manipal Definition - PPCM - Dilated cardiomyopathy of unknown cause resulting in cardiac failure that occurs in the peripartum period in women without any preexisting
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationJournal of the American College of Cardiology Vol. 52, No. 24, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 52, No. 24, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.09.011
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationMy Patient Needs a Stress Test
My Patient Needs a Stress Test Amy S. Burhanna,, MD, FACC Coastal Cardiology Cape May Court House, New Jersey Absolute and relative contraindications to exercise testing Absolute Acute myocardial infarction
More informationThe Patient with Atrial Fibrilation
Assessment of Diastolic Function The Patient with Atrial Fibrilation Assoc. Prof. Adriana Ilieşiu, FESC University of Medicine Carol Davila Bucharest, Romania Associated Conditions with Atrial Fibrillation
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationIndex of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125
145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationMethods. Washington, DC and Hines, Illinois
942 JACC Vol. 32, No. 4 Prevalence and Significance of Nonsustained Ventricular Tachycardia in Patients With Premature Ventricular Contractions and Heart Failure Treated With Vasodilator Therapy STEVEN
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationNew Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD
New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone
More information